CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03134872
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:41.294614+00:00
Published At: 2020-06-09T00:00:00+00:00
Record Updated At: 2020-06-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Lung Diseases", "Respiratory Tract Disease", "Neoplasms by Site", "Neoplasm, Bronchial", "Carcinoma, Bronchogenic"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-06-09"
protocolSection.identificationModule.nctId: "NCT03134872"
protocolSection.identificationModule.officialTitle: "A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.